Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation

Background: Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3-Internal Tandem Duplication (ITD) mutation have a poor prognosis and high risk of relapse, even after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Prevention of disease relapse remains a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chen Liang, Donglin Yang, Aiming Pang, Yi He, Rongli Zhang, Weihua Zhai, Sizhou Feng, Mingzhe Han, Suning Chen, Liping Dou, Yu Wang, Xiaojin Wu, Erlie Jiang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Hematology
Témata:	Acute myeloid leukemia FLT3-ITD hematopoietic stem cell transplantation relapsed/refractory disease FLT3 inhibitor Gilteritinib
On-line přístup:	https://www.tandfonline.com/doi/10.1080/16078454.2025.2509353
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!